Wednesday, December 9, 2020

Rocket Pharma +33.6% after positive early data in Danon disease Phase 1 trial

RP-A501 is Rocket's adeno-associated viral vector-based gene therapy candidate expressing LAMP2B for the treatment of Danon disease, a rare ...
http://dlvr.it/RnKn21
-

No comments:

Post a Comment

Note: Only a member of this blog may post a comment.

Subscribe to: Post Comments (Atom)

2 muggers captured by RU students on campus - UNB

Rayhanul Ferdous, a student of Genetic Engineering and Biotechnology department who had his phone stolen told UNB: “I was walking on the eas...